Literature DB >> 24619234

Chinese medicine syndrome distribution of chronic hepatitis B virus carriers in immunotolerant phase.

He-ping Xie1, Hong-zhi Yang, Wei-kang Wu, Wei-bing Guan, Qian-shan Ke, Yong-wei Li, Min Dai, Ge-min Xiao, Jiong-shan Zhang, Yang-mei Li.   

Abstract

OBJECTIVE: To explore Chinese medicine (CM) syndrome distribution of chronic hepatitis B virus (HBV) carriers in immunotolerant phase (ITP).
METHODS: One hundred and eighty-five chronic HBV carriers in ITP, seen in the Third Affiliated Hospital of Sun Yat-sen University from May 2009 to December 2010, were admitted in an observational study under the guidance of CM. Patients' CM symptoms and signs, demographics, liver biochemistries, and qualitative HBV DNA were recorded in the questionnaires. CM syndromes were then differentiated to 15 detailed types and analyzed by generalization. Lastly, the location, pathogenic factors and nature of the disease were also assessed.
RESULTS: When CM syndrome patterns were differentiated to 15 types, there were 27 (15%) no syndrome cases, 94 (50%) single syndrome cases and 64 (35%) compound syndromes cases. The main detailed syndromes included Liver (Gan)-qi depression (LQD), Kidney (Shen)-qi deficiency (KQD), Spleen (Pi)-qi deficiency (SQD) and Kidney-yang deficiency (KYAD). After CM syndromes generalized to five types, their frequency was Spleen-Kidney deficiency (SKD)>LQD>inner dampness-heat retention (IDHR)>Liver-Kidney deficiency (LKD)>blood stasis blocking collateral (BSBC). SKD and LQD occupied 64%. The disease location included Liver, Gallbladder (Dan), Spleen, Stomach (Wei) and Kidney. The pathogenic factors were mainly qi stagnation, qi deficiency, yang deficiency, concurrently dampness-heat and blood stasis. The deficiency syndrome was more than excess syndrome in its nature.
CONCLUSIONS: Most of chronic HBV carriers in ITP have their CM syndrome, and the most common types are SKAD, LQD. This study suggests that the natural history may be improved through breaking the state of immune tolerance or shorten the time of ITP by strengthening Spleen-Kidney and reliving Liver qi.

Entities:  

Mesh:

Year:  2014        PMID: 24619234     DOI: 10.1007/s11655-013-1569-5

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  23 in total

1.  [Set clinical therapeutic guideline in traditional medicine urgently].

Authors:  Jun Song; Ke-ji Chen
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2006-07

2.  [The guidelines of prevention and treatment for chronic hepatitis B].

Authors: 
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2005-12

3.  Hepatitis B in China.

Authors:  Jie Liu; Daiming Fan
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

Review 4.  EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Authors: 
Journal:  J Hepatol       Date:  2008-10-29       Impact factor: 25.083

5.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

Review 6.  Treatment of chronic hepatitis B.

Authors:  M Cornberg; J Jaroszewicz; M P Manns; H Wedemeyer
Journal:  Minerva Gastroenterol Dietol       Date:  2010-12

Review 7.  Epidemiology of hepatitis B and C viruses: a global overview.

Authors:  Helen S Te; Donald M Jensen
Journal:  Clin Liver Dis       Date:  2010-02       Impact factor: 6.126

8.  Hepatitis B virus infection.

Authors:  Yun-Fan Liaw; Chia-Ming Chu
Journal:  Lancet       Date:  2009-02-14       Impact factor: 79.321

Review 9.  Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.

Authors:  Yun-Fan Liaw
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

10.  Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

Authors:  Xiaofeng Liang; Shengli Bi; Weizhong Yang; Longde Wang; Gang Cui; Fuqiang Cui; Yong Zhang; Jianhua Liu; Xiaohong Gong; Yuansheng Chen; Fuzhen Wang; Hui Zheng; Feng Wang; Jing Guo; Zhiyuan Jia; Jingchen Ma; Huaqing Wang; Huiming Luo; Li Li; Shuigao Jin; Stephen C Hadler; Yu Wang
Journal:  Vaccine       Date:  2009-09-01       Impact factor: 3.641

View more
  4 in total

1.  The Score Model Containing Chinese Medicine Syndrome Element of Blood Stasis Presented a Better Performance Compared to APRI and FIB-4 in Diagnosing Advanced Fibrosis in Patients with Chronic Hepatitis B.

Authors:  Xiao-Ling Chi; Mei-Jie Shi; Huan-Ming Xiao; Yu-Bao Xie; Gao-Shu Cai
Journal:  Evid Based Complement Alternat Med       Date:  2016-01-20       Impact factor: 2.629

2.  HLA-DQB1/DRB1 Alleles Associate with Traditional Chinese Medicine Syndrome of Chronic Hepatitis B: A Potential Predictor of Progression.

Authors:  Xiyang Liu; Tingjun Wan; Sijie Dang; Dong Wang; Cen Jiang; Yue Su; Mengmeng Shen; Xuchen Tang; Xia Li; Baixue Li; Li Wen; Quansheng Feng
Journal:  Biomed Res Int       Date:  2019-11-21       Impact factor: 3.411

3.  Biological Differentiation of Dampness-Heat Syndromes in Chronic Hepatitis B: From Comparative MicroRNA Microarray Profiling to Biomarker Identification.

Authors:  Li Wen; Cen Jiang; Ting-Jun Wan; Dong Wang; Di Yan; Gui-Yu Li; Yue Su; Xi-Yang Liu; Li-Jun Rong; Hua Ye; Bai-Xue Li; Quan-Sheng Feng
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-20       Impact factor: 2.629

4.  Traditional Chinese Medicine Syndrome Patterns and Their Association with Hepatitis B Surface Antigen Levels during the Natural History of Chronic Hepatitis B Virus Infection.

Authors:  He-Ping Xie; Zhi-Ping Liu; Jiong-Shan Zhang; Min Dai; Ge-Min Xiao; Wei-Kang Wu; Hong-Zhi Yang
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-02       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.